Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 209

1.

Three-Dimensional Cell Cultures in Drug Discovery and Development.

Fang Y, Eglen RM.

SLAS Discov. 2017 Jun;22(5):456-472. doi: 10.1177/1087057117696795.

2.

Three-Dimensional Cell Culture: A Rapidly Emerging Approach to Cellular Science and Drug Discovery.

Eglen RM, Klein JL.

SLAS Discov. 2017 Jun;22(5):453-455. doi: 10.1177/2472555217702448. No abstract available.

PMID:
28520520
3.

Drug Discovery Goes Three-Dimensional: Goodbye to Flat High-Throughput Screening?

Eglen RM, Randle DH.

Assay Drug Dev Technol. 2015 Jun;13(5):262-5. doi: 10.1089/adt.2015.647. Epub 2015 Jun 29.

PMID:
26121065
4.

Overview of muscarinic receptor subtypes.

Eglen RM.

Handb Exp Pharmacol. 2012;(208):3-28. doi: 10.1007/978-3-642-23274-9_1. Review.

PMID:
22222692
5.

Screening for compounds that modulate epigenetic regulation of the transcriptome: an overview.

Eglen RM, Reisine T.

J Biomol Screen. 2011 Dec;16(10):1137-52. doi: 10.1177/1087057111417871. Epub 2011 Oct 14. Review.

PMID:
22002420
6.

Human kinome drug discovery and the emerging importance of atypical allosteric inhibitors.

Eglen RM, Reisine T.

Expert Opin Drug Discov. 2010 Mar;5(3):277-90. doi: 10.1517/17460441003636820. Epub 2010 Feb 18.

PMID:
22823023
7.

New insights into GPCR function: implications for HTS.

Eglen RM, Reisine T.

Methods Mol Biol. 2009;552:1-13. doi: 10.1007/978-1-60327-317-6_1. Review.

PMID:
19513638
8.

The current status of drug discovery against the human kinome.

Eglen RM, Reisine T.

Assay Drug Dev Technol. 2009 Feb;7(1):22-43. doi: 10.1089/adt.2008.164. Review.

PMID:
19382888
9.

Photoproteins: important new tools in drug discovery.

Eglen RM, Reisine T.

Assay Drug Dev Technol. 2008 Oct;6(5):659-71. doi: 10.1089/adt.2008.160. Review.

PMID:
19035847
10.

Current trends in high-throughput screening.

Sterling J, Bojanic D, Eglen RM, Heyse S, Strulovici B.

Assay Drug Dev Technol. 2008 Aug;6(4):491-504. doi: 10.1089/adt.2008.9989. No abstract available.

PMID:
18795872
11.

An overview of drug screening using primary and embryonic stem cells.

Eglen RM, Gilchrist A, Reisine T.

Comb Chem High Throughput Screen. 2008 Aug;11(7):566-72. Review.

PMID:
18694393
12.

The use of immortalized cell lines in GPCR screening: the good, bad and ugly.

Eglen RM, Gilchrist A, Reisine T.

Comb Chem High Throughput Screen. 2008 Aug;11(7):560-5. Review.

PMID:
18694392
13.

The use of AlphaScreen technology in HTS: current status.

Eglen RM, Reisine T, Roby P, Rouleau N, Illy C, Bossé R, Bielefeld M.

Curr Chem Genomics. 2008 Feb 25;1:2-10. doi: 10.2174/1875397300801010002.

14.

Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development.

Wess J, Eglen RM, Gautam D.

Nat Rev Drug Discov. 2007 Sep;6(9):721-33. Review.

PMID:
17762886
15.
16.

Assessing GPCR activation using protein complementation: a novel technique for HTS.

Eglen RM.

Biochem Soc Trans. 2007 Aug;35(Pt 4):746-8. Review.

PMID:
17635139
17.

Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery.

Olson KR, Eglen RM.

Assay Drug Dev Technol. 2007 Feb;5(1):137-44. Review.

PMID:
17355206
18.

Using ligand-induced conformational change to screen for compounds targeting G-protein-coupled receptors.

O'Dowd BF, Alijaniaram M, Ji X, Nguyen T, Eglen RM, George SR.

J Biomol Screen. 2007 Mar;12(2):175-85. Epub 2007 Feb 8.

PMID:
17289935
19.

An interview with Richard M. Eglen, Ph.D.

Eglen RM.

Assay Drug Dev Technol. 2006 Oct;4(5):503-9. No abstract available.

PMID:
17115921
20.

Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function.

Eglen RM.

Auton Autacoid Pharmacol. 2006 Jul;26(3):219-33. Review.

PMID:
16879488
21.

A homogeneous cell-based assay to measure nuclear translocation using beta-galactosidase enzyme fragment complementation.

Fung P, Peng K, Kobel P, Dotimas H, Kauffman L, Olson K, Eglen RM.

Assay Drug Dev Technol. 2006 Jun;4(3):263-72.

PMID:
16834532
22.

A generic, homogenous method for measuring kinase and inhibitor activity via adenosine 5'-diphosphate accumulation.

Charter NW, Kauffman L, Singh R, Eglen RM.

J Biomol Screen. 2006 Jun;11(4):390-9. Epub 2006 Apr 28.

PMID:
16751335
23.

Antibody-free method for protein detection on blots using enzyme fragment complementation.

Horecka J, Charter NW, Bosano BL, Fung P, Kobel P, Peng K, Eglen RM.

Biotechniques. 2006 Mar;40(3):381-3. No abstract available.

24.

Emerging concepts in GPCR function--the influence of cell phenotype on GPCR pharmacology.

Eglen RM.

Proc West Pharmacol Soc. 2005;48:31-4. Review.

PMID:
16416655
25.

Functional G protein-coupled receptor assays for primary and secondary screening.

Eglen RM.

Comb Chem High Throughput Screen. 2005 Jun;8(4):311-8. Review.

PMID:
16101007
26.

Muscarinic receptor subtype pharmacology and physiology.

Eglen RM.

Prog Med Chem. 2005;43:105-36. Review. No abstract available.

PMID:
15850824
27.

Harmane and harmalan are bioactive components of classical clonidine-displacing substance.

Parker CA, Anderson NJ, Robinson ES, Price R, Tyacke RJ, Husbands SM, Dillon MP, Eglen RM, Hudson AL, Nutt DJ, Crump MP, Crosby J.

Biochemistry. 2004 Dec 28;43(51):16385-92.

PMID:
15610033
28.

High-throughput screening using label-free technologies.

Eglen RM, Pribilla I.

J Biomol Screen. 2004 Sep;9(6):465-6. No abstract available.

PMID:
15452332
29.

Identifying orphan G protein coupled receptors in drug discovery.

Dunlop J, Eglen RM.

Drug Discov Today Technol. 2004 Sep;1(1):61-8. doi: 10.1016/j.ddtec.2004.06.004.

PMID:
24981269
30.

Beta galactosidase enzyme fragment complementation as a high-throughput screening protease technology.

Naqvi T, Lim A, Rouhani R, Singh R, Eglen RM.

J Biomol Screen. 2004 Aug;9(5):398-408.

PMID:
15296639
31.

Homogeneous assays for cellular protein degradation using beta-galactosidase complementation: NF-kappaB/IkappaB pathway signaling.

Zhao X, Vainshtein I, Gellibolian R, Shu Y, Dotimas H, Wang XM, Fung P, Horecka J, Bosano BL, Eglen RM.

Assay Drug Dev Technol. 2003 Dec;1(6):823-33.

PMID:
15090228
32.

Enzyme fragment complementation: a flexible high throughput screening assay technology.

Eglen RM.

Assay Drug Dev Technol. 2002 Nov;1(1 Pt 1):97-104.

PMID:
15090161
33.

No evidence for activation of alpha(2)-adrenoceptors by methanolic extracts of bovine brain and lung containing clonidine-displacing substance.

Pinthong D, Kendall DA, Maclennan SJ, Eglen RM, Wilson VG.

Ann N Y Acad Sci. 2003 Dec;1009:201-15.

PMID:
15028589
34.

A high-throughput, nonisotopic, competitive binding assay for kinases using nonselective inhibitor probes (ED-NSIP).

Vainshtein I, Silveria S, Kaul P, Rouhani R, Eglen RM, Wang J.

J Biomol Screen. 2002 Dec;7(6):507-14.

PMID:
14599348
35.

Beta galactosidase enzyme fragment complementation as a novel technology for high throughput screening.

Eglen RM, Singh R.

Comb Chem High Throughput Screen. 2003 Jun;6(4):381-7. Review.

PMID:
12769682
36.

High-affinity interactions of ligands at recombinant guinea pig 5HT7 receptors.

Wilcox RE, Ragan JE, Pearlman RS, Brusniak MY, Eglen RM, Bonhaus DW, Tenner TE Jr, Miller JD.

J Comput Aided Mol Des. 2001 Oct;15(10):883-909.

PMID:
11918075
37.
38.

Therapeutic opportunities from muscarinic receptor research.

Eglen RM, Choppin A, Watson N.

Trends Pharmacol Sci. 2001 Aug;22(8):409-14. Review.

PMID:
11479003
39.

Regulation of Na+ channel distribution in the nervous system.

Novakovic SD, Eglen RM, Hunter JC.

Trends Neurosci. 2001 Aug;24(8):473-8. Review.

PMID:
11476887
40.

Muscarinic receptors and gastrointestinal tract smooth muscle function.

Eglen RM.

Life Sci. 2001 Apr 27;68(22-23):2573-8. Review.

PMID:
11392628
41.

Functional characterization of rat submaxillary gland muscarinic receptors using microphysiometry.

Meloy TD, Daniels DV, Hegde SS, Eglen RM, Ford AP.

Br J Pharmacol. 2001 Apr;132(7):1606-14.

42.
43.

Pharmacological properties of 5-Hydroxytryptamine(4) receptor antagonists on constitutively active wild-type and mutated receptors.

Claeysen S, Sebben M, Bécamel C, Eglen RM, Clark RD, Bockaert J, Dumuis A.

Mol Pharmacol. 2000 Jul;58(1):136-44.

44.

High Throughput Screening: Myths and Future Realities.

Eglen RM.

J Biomol Screen. 1999;4(4):179-182. No abstract available.

PMID:
10838436
45.

The muscarinic M(5) receptor: a silent or emerging subtype?

Eglen RM, Nahorski SR.

Br J Pharmacol. 2000 May;130(1):13-21. Review. No abstract available.

46.
48.
49.

Differential distribution of the tetrodotoxin-sensitive rPN4/NaCh6/Scn8a sodium channel in the nervous system.

Tzoumaka E, Tischler AC, Sangameswaran L, Eglen RM, Hunter JC, Novakovic SD.

J Neurosci Res. 2000 Apr 1;60(1):37-44.

PMID:
10723066
50.

Isolation of RP-HPLC pure clonidine-displacing substance from NG108-15 cells.

Parker CA, Hudson AL, Nutt DJ, Dillon MP, Eglen RM, Crosby J.

Eur J Pharmacol. 2000 Jan 3;387(1):27-30.

PMID:
10633156

Supplemental Content

Loading ...
Support Center